@article{petrus-reurer-2022-35705015,
  author = {Petrus-Reurer S and Lederer AR and Baque-Vidal L and Douagi I and Pannagel B and Khven I and Aronsson M and Bartuma H and Wagner M and Wrona A and Efstathopoulos P and Jaberi E and Willenbrock H and Shimizu Y and Villaescusa JC and Andre H and Sundstr”ßm E and Bhaduri A and Kriegstein A and Kvanta A and La Manno G and Lanner F},
  title = {{Molecular profiling of stem cell-derived retinal pigment epithelial cell differentiation established for clinical translation}},
  journal = {Stem Cell Reports},
  year = {2022},
  volume = {17},
  number = {6},
  pages = {1458-1475},
  doi = {10.1016/j.stemcr.2022.05.005},
  abstract = {Human embryonic stem cell-derived retinal pigment epithelial cells (hESC-RPE) are a promising cell source to treat age-related macular degeneration (AMD). Despite several ongoing clinical studies, a detailed mapping of transient cellular states during in vitro differentiation has not been performed. Here, we conduct single-cell transcriptomic profiling of an hESC-RPE differentiation protocol that has been developed for clinical use. Differentiation progressed through a culture diversification recapitulating early embryonic development, whereby cells rapidly acquired a rostral embryo patterning signature before converging toward the RPE lineage. At intermediate steps, we identified and examined the potency of an NCAM1(+) retinal progenitor population and showed the ability of the protocol to suppress non-RPE fates. We demonstrated that the method produces a pure RPE pool capable of maturing further after subretinal transplantation in a large-eyed animal model. Our evaluation of hESC-RPE differentiation supports the development of safe and efficient pluripotent stem cell-based therapies for AMD.},
  pmid = {35705015}
}
